EL7.AI
StocksMedium•30 March 2026•
1 min read

Jefferies Reaffirms Buy Rating for Verastem While Lowering Price Target to $15

Key Facts

1Jefferies Financial Group reaffirmed its 'Buy' rating for Verastem (VSTM) but lowered the price target from $19.00 to $15.00.
2The company reported mixed quarterly results, missing EPS estimates but exceeding revenue expectations.
3Institutional investors hold a substantial portion of the company, while some insiders have recently sold shares.

Jefferies Financial Group has reaffirmed its 'Buy' rating for Verastem (VSTM), though it lowered its price target from $19.00 to $15.00. The adjustment follows the biotechnology company's report of mixed quarterly financial results. While Verastem's revenue exceeded market expectations, the company missed analyst estimates for earnings per share (EPS). The revised price target reflects a strategic balance between strong revenue growth and ongoing operational hurdles. Institutional investors continue to maintain a substantial stake in the company, signaling long-term confidence in its clinical pipeline. However, recent insider selling activity has introduced a note of caution for some market participants. Despite the target reduction, the new $15.00 valuation still implies significant upside potential from current trading levels.